Amidst a mental health epidemic in the U.S., a rising number of individuals suffer from conditions like PTSD. Traditional treatments, while effective for many, may not suit every patient. Recognising this, a new approach involving neuro-biomarkers is gaining ground.
Biomarkers, objective biological signals, have transformed healthcare. But using them to identify and manage neurological disorders has faced challenges due to biological barriers. To overcome these barriers, researchers have merged EEG and fMRI technologies, creating affordable solutions to monitor deep brain activity.
These biomarkers provide real-time data-driven insights into the underlying mechanisms of mental disorders, with a particular focus on regions like the amygdala, which plays a central role in various mental disorders.
Tech-powered neuro-biomarkers offer a third option alongside existing treatments, with customisation and progress monitoring. Integrated with automation and machine learning, they have the potential to address a wider range of neurological conditions, promising more effective and impactful mental disorder care.
Click here to read the original news story.